The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer

INT131 (formerly T0903131, T131, AMG131) is a potent non-thiazolidinedione (TZD) selective Peroxisome Proliferator-activated Receptor gamma modulator (SPPARM) currently in Phase 2 clinical trials for treatment of type-2 diabetes mellitus (T2DM). This new chemical entity represents a second generation SPPARM approach developed after the first generation PPARgamma full agonists to address their inherent limitations. INT131 was specifically and carefully designed using preclinical models to exhibit a biological profile of strong efficacy with de minimis side effects compared to PPARgamma full agonists. As a potent PPARgamma modulator, INT131 binds to PPARgamma with high affinity. In pharmacology models of diabetes and in early clinical studies, it achieved a high level of efficacy in terms of antidiabetic actions such as Insulin sensitization and glucose and Insulin lowering, but had little activity in terms of other, undesired, effects associated with TZD PPARgamma full agonists such as edema and adipogenesis. Ongoing clinical development is directed at translating these findings into establishing a novel and effective treatment for T2DM patients with an improved safety profile in relation to that currently available.